ASX - By Stock
|
KZA |
Re:
Ann: Notification regarding unquoted securities - KZA
|
|
pohutukawa
|
20 |
5.2K |
11 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
20
|
5.2K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
pohutukawa
|
47 |
13K |
1 |
03/12/22 |
03/12/22 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
pohutukawa
|
47 |
13K |
1 |
02/12/22 |
02/12/22 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Withdrawal of resolution
|
|
pohutukawa
|
18 |
6.9K |
3 |
03/11/22 |
03/11/22 |
ASX - By Stock
|
18
|
6.9K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia releases final data from P2 paxalisib trial
|
|
pohutukawa
|
107 |
33K |
6 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
107
|
33K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Retraction of Grant Announcement
|
|
pohutukawa
|
57 |
19K |
0 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
57
|
19K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: 2021 AGM Letter to Shareholders and Proxy
|
|
pohutukawa
|
26 |
6.2K |
3 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
26
|
6.2K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
MEIP question
|
|
pohutukawa
|
6 |
1.8K |
0 |
03/09/21 |
03/09/21 |
ASX - By Stock
|
6
|
1.8K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
MEIP question
|
|
pohutukawa
|
6 |
1.8K |
0 |
03/09/21 |
03/09/21 |
ASX - By Stock
|
6
|
1.8K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
|
|
pohutukawa
|
28 |
9.5K |
11 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
28
|
9.5K
|
11
|
|
ASX - By Stock
|
BRL |
Re:
Ann: Supreme Court upholds Bathurst's appeal
|
|
pohutukawa
|
54 |
24K |
4 |
14/07/21 |
14/07/21 |
ASX - By Stock
|
54
|
24K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Patent Grant
|
|
pohutukawa
|
46 |
13K |
9 |
12/06/21 |
12/06/21 |
ASX - By Stock
|
46
|
13K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pause in Trading
|
|
pohutukawa
|
17 |
5.8K |
5 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
17
|
5.8K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
PI3K Drugs for Alzheimers
|
|
pohutukawa
|
73 |
25K |
1 |
19/04/21 |
19/04/21 |
ASX - By Stock
|
73
|
25K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
pohutukawa
|
114 |
34K |
10 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
114
|
34K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Trial Advances to Final Stage
|
|
pohutukawa
|
7 |
3.6K |
3 |
08/03/21 |
08/03/21 |
ASX - By Stock
|
7
|
3.6K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Trial Advances to Final Stage
|
|
pohutukawa
|
7 |
3.6K |
2 |
08/03/21 |
08/03/21 |
ASX - By Stock
|
7
|
3.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Presents to H.C. Wainwright Global Conference
|
|
pohutukawa
|
2 |
1.9K |
11 |
05/03/21 |
05/03/21 |
ASX - By Stock
|
2
|
1.9K
|
11
|
|
ASX - By Stock
|
TRU |
Re:
Ann: TruScreen Executive Leadership Change
|
|
pohutukawa
|
8 |
2.8K |
3 |
02/03/21 |
02/03/21 |
ASX - By Stock
|
8
|
2.8K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
closest to the pin , tomorrow and month end
|
|
pohutukawa
|
18 |
6.9K |
5 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
18
|
6.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
closest to the pin , tomorrow and month end
|
|
pohutukawa
|
18 |
6.9K |
5 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
18
|
6.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
large sales
|
|
pohutukawa
|
8 |
3.4K |
2 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
8
|
3.4K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Hopper et al
|
|
pohutukawa
|
21 |
5.4K |
3 |
27/06/20 |
27/06/20 |
ASX - By Stock
|
21
|
5.4K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
COVID IND
|
|
pohutukawa
|
10 |
4.2K |
5 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
10
|
4.2K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
COVID IND
|
|
pohutukawa
|
10 |
4.2K |
9 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
10
|
4.2K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Investigating Potential COVID-19 Treatment
|
|
pohutukawa
|
34 |
18K |
4 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
34
|
18K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: FDA grants IND approval to Veyonda
|
|
pohutukawa
|
21 |
56K |
2 |
23/02/20 |
23/02/20 |
ASX - By Stock
|
21
|
56K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: FDA grants IND approval to Veyonda
|
|
pohutukawa
|
21 |
56K |
0 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
21
|
56K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: FDA grants IND approval to Veyonda
|
|
pohutukawa
|
21 |
56K |
0 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
21
|
56K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: FDA grants IND approval to Veyonda
|
|
pohutukawa
|
21 |
56K |
2 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
21
|
56K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia Half Year Accounts and Chairman's letter
|
|
pohutukawa
|
103 |
49K |
3 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
103
|
49K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Alliance With GenesisCare
|
|
pohutukawa
|
8 |
4.1K |
1 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
8
|
4.1K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Alliance With GenesisCare
|
|
pohutukawa
|
8 |
4.1K |
4 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
8
|
4.1K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Interesting
|
|
pohutukawa
|
112 |
49K |
5 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
112
|
49K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: AU$2.4m Increase to Funding Agreement
|
|
pohutukawa
|
8 |
6.6K |
0 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
8
|
6.6K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pronounced survival benefit in LuPIN interim trial data
|
|
pohutukawa
|
11 |
3.8K |
0 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
11
|
3.8K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: $8.1M Financing & Re-Set of Capital Structure
|
|
pohutukawa
|
15 |
6.8K |
1 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
15
|
6.8K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pronounced survival benefit in LuPIN interim trial data
|
|
pohutukawa
|
11 |
3.8K |
6 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
11
|
3.8K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Latest Edison Report Values KZA at $1.91 per share
|
|
pohutukawa
|
30 |
10K |
10 |
15/01/20 |
15/01/20 |
ASX - By Stock
|
30
|
10K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia joins GBM Agile
|
|
pohutukawa
|
157 |
67K |
5 |
11/12/19 |
11/12/19 |
ASX - By Stock
|
157
|
67K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Prospects
|
|
pohutukawa
|
2 |
2.3K |
5 |
05/12/19 |
05/12/19 |
ASX - By Stock
|
2
|
2.3K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
How Do You Value Kazia
|
|
pohutukawa
|
62 |
33K |
3 |
22/11/19 |
22/11/19 |
ASX - By Stock
|
62
|
33K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
How Do You Value Kazia
|
|
pohutukawa
|
62 |
33K |
9 |
22/11/19 |
22/11/19 |
ASX - By Stock
|
62
|
33K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
pohutukawa
|
92 |
35K |
2 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
92
|
35K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
pohutukawa
|
92 |
35K |
2 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
92
|
35K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
pohutukawa
|
92 |
35K |
2 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
92
|
35K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
pohutukawa
|
92 |
35K |
5 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
92
|
35K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
pohutukawa
|
92 |
35K |
3 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
92
|
35K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Executive Appointments and Board Change
|
|
pohutukawa
|
25 |
9.1K |
2 |
21/10/19 |
21/10/19 |
ASX - By Stock
|
25
|
9.1K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Executive Appointments and Board Change
|
|
pohutukawa
|
25 |
9.1K |
6 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
25
|
9.1K
|
6
|
|